-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

Benzinga·07/21/2026 12:29:55
Listen to the news
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $34 to $36.